Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, in New Delhi, India.
The presentation, scheduled for October 3rd, will focus on the evaluation of oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). Professor Paul Hofman, MD, from the Liggins Institute, University of Auckland, New Zealand, will deliver the presentation titled 'Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial'.
Lumos Pharma, Inc. (NASDAQ:LUMO) ha annunciato che un'analisi aggiornata dei dati del suo trial clinico di Fase 2 OraGrowtH210 è stata accettata per la presentazione al 13° Congresso Scientifico Biennale della Società di Endocrinologia Pediatrica della Regione Asia-Pacifico (APPES 2024). L'evento si svolgerà dal 2 al 5 ottobre 2024 a Nuova Delhi, India.
La presentazione, prevista per il 3 ottobre, si concentrerà sulla valutazione di LUM-201 orale per la Deficienza da Ormoni della Crescita Pediatrica (PGHD). Il Professor Paul Hofman, MD, dell'Istituto Liggins, Università di Auckland, Nuova Zelanda, terrà la presentazione intitolata 'Risposte di Crescita, IGF-1 e IGFBP-3 all'ormone della crescita orale (GH) secretagogo, LUM-201, nella Deficienza da Ormoni della Crescita Pediatrica (PGHD) nel trial OraGrowtH210'.
Lumos Pharma, Inc. (NASDAQ:LUMO) anunció que un análisis actualizado de los datos de su ensayo clínico de Fase 2 OraGrowtH210 ha sido aceptado para su presentación en el 13º Encuentro Científico Bienal de la Sociedad de Endocrinología Pediátrica de Asia-Pacífico (APPES 2024). El evento se llevará a cabo del 2 al 5 de octubre de 2024 en Nueva Delhi, India.
La presentación, programada para el 3 de octubre, se centrará en la evaluación de LUM-201 oral para la Deficiencia de Hormona del Crecimiento Pediátrica (PGHD). El Profesor Paul Hofman, MD, del Instituto Liggins, Universidad de Auckland, Nueva Zelanda, ofrecerá la presentación titulada 'Crecimiento, Respuestas de IGF-1 e IGFBP-3 al Secretagogo Oral de Hormona del Crecimiento (GH), LUM-201, en la Deficiencia de Hormona del Crecimiento Pediátrica (PGHD) en el ensayo OraGrowtH210'.
Lumos Pharma, Inc. (NASDAQ:LUMO)는 2상 OraGrowtH210 임상시험 데이터에 대한 업데이트된 분석이 아시아 태평양 소아내분비학회(APPES 2024) 제13회 과학 회의에서 발표되기로 승인되었음을 발표했습니다. 이 행사는 2024년 10월 2일부터 5일까지 인도 뉴델리에서 개최됩니다.
10월 3일로 예정된 발표는 소아 성장 호르몬 결핍(PGHD)에 대한 경구 LUM-201의 평가에 중점을 두고 있습니다. 뉴질랜드 오클랜드 대학의 리긴스 연구소 소속인 Paul Hofman 교수(MD)가 'OraGrowtH210 시험에서 소아 성장 호르몬 결핍(PGHD)에 대한 경구 성장 호르몬(GH) 비밀 분비제 LUM-201의 성장, IGF-1 및 IGFBP-3 반응'이라는 제목의 발표를 진행할 예정입니다.
Lumos Pharma, Inc. (NASDAQ:LUMO) a annoncé qu'une analyse mise à jour des données de son essai clinique de Phase 2 OraGrowtH210 a été acceptée pour présentation lors de la 13ème Réunion Scientifique Biennale de la Société d'Endocrinologie Pédiatrique de la région Asie-Pacifique (APPES 2024). L'événement se déroulera du 2 au 5 octobre 2024 à New Delhi, en Inde.
La présentation, prévue pour le 3 octobre, se concentrera sur l'évaluation de LUM-201 oral pour la Déficience en Hormone de Croissance Pédiatrique (PGHD). Le professeur Paul Hofman, MD, de l'Institut Liggins, Université d'Auckland, Nouvelle-Zélande, fera la présentation intitulée 'Croissance, réponses d'IGF-1 et d'IGFBP-3 à l'agent sécrétagogue d'hormone de croissance orale (GH), LUM-201, dans la Déficience en Hormone de Croissance Pédiatrique (PGHD) dans l'essai OraGrowtH210'.
Lumos Pharma, Inc. (NASDAQ:LUMO) gab bekannt, dass eine aktualisierte Analyse der Daten aus seiner Phase-2-Studie OraGrowtH210 zur Präsentation beim 13. Biennalen Wissenschaftlichen Treffen der Asia Pacific Pediatric Endocrine Society (APPES 2024) angenommen wurde. Die Veranstaltung findet vom 2. bis 5. Oktober 2024 in Neu-Delhi, Indien, statt.
Die Präsentation, die für den 3. Oktober geplant ist, wird sich auf die Bewertung von oralen LUM-201 bei pädiatrischer Wachstums-Hormon-Mangel (PGHD) konzentrieren. Professor Paul Hofman, MD, vom Liggins Institute der Universität Auckland, Neuseeland, wird die Präsentation mit dem Titel 'Wachstum, IGF-1 und IGFBP-3-Reaktionen auf das orale Wachstumshormon (GH)-Sekretagogum LUM-201 bei pädiatrischem Wachstums-Hormon-Mangel (PGHD) in der OraGrowtH210-Studie' halten.
- Phase 2 clinical trial data accepted for presentation at a major international conference
- Potential advancement in treatment for Pediatric Growth Hormone Deficiency (PGHD)
- Increased visibility for Lumos Pharma's research in the pediatric endocrinology community
- None.
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.
Abstract Presentation: Thursday, October 3rd – Oral Session: Growth & Puberty – 2:30PM Local Time
- Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial (Paul Hofman, MD, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
What is the main focus of Lumos Pharma's presentation at APPES 2024?
When and where will Lumos Pharma (LUMO) present its clinical trial results?
Who will be presenting Lumos Pharma's (LUMO) clinical trial data at APPES 2024?
What is the title of Lumos Pharma's (LUMO) presentation at APPES 2024?
